title: Spanish multicenter tafluprost tolerability study.
abstract: OBJECTIVE
  To evaluate the ocular surface symptoms and signs associated with preservative-free 0.0015% tafluprost in patients with glaucoma or ocular hypertension (OHT).
  
  
  METHODS
  Prospective non-interventional, multicentre, observational study on 134 patients, naive or on previous treatment with another prostaglandin analogue. In each visit (V1 baseline visit, V2 at 1 month and V3 at 3 months), patients evaluated five ocular surface symptoms as: absent, mild, moderate and severe. Parallelly, the ophthalmologist assessed the tear break-up time, keratitis, conjunctival hyperaemia, blepharitis, Schirmer test and tear meniscus.
  
  
  RESULTS
  Patients with OHT (n=71, 53%) experienced a statistically significant improvement of all symptoms: stinging/burning/irritation, itching, foreign body sensation, tearing and dryness sensation at V3, while glaucoma patients improved all symptoms at both V2 and V3. In patients with OHT, all signs except Schirmer test improved and the decrease in hyperaemia was statistically significant. Eyes with glaucoma ameliorated the keratitis, hyperaemia and tear meniscus at V2 and V3 and the break-up time and blepharitis at V3. In the subset of patients with previous treatment (n=79, 58.9%), patients with OHT presented significant improvement of hyperaemia, yet the rest of signs did not decrease significantly or remained unchanged, while in patients with glaucoma all signs improved significantly at both visits. The intraocular pressure (IOP) drop in naive eyes was 22.2% (24.7-19.7 mm Hg) in OHT and 29.5% (33.7-25.3 mm Hg) in glaucoma eyes. In previously treated eyes, no statistically significant change in IOP was found.
  
  
  CONCLUSIONS
  Preservative-free tafluprost is a well tolerated hypotensive agent that can be used in eyes with surface problems and in naive eyes.
authors.affiliation: Glaucoma and Genetics Unit, Institut Comtal d'Oftalmologia, Via Augusta 48-54, 2n 08006 BCN Barcelona, Spain. emillaright@gmail.com
authors.forename: Elena
authors.initials: E
authors.lastname: Milla
authors.forename: Oana
authors.initials: O
authors.lastname: Stirbu
authors.forename: Amanda
authors.initials: A
authors.lastname: Rey
authors.forename: Susana
authors.initials: S
authors.lastname: Duch
authors.forename: Oscar
authors.initials: O
authors.lastname: Buchacra
authors.forename: Amelia
authors.initials: A
authors.lastname: Robles
authors.forename: Catalina
authors.initials: C
authors.lastname: Navarro
authors.forename: Rafael
authors.initials: R
authors.lastname: Gil
authors.forename: Jose Maria
authors.initials: JM
authors.lastname: Cordero
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003228:Conjunctiva / Q000187:drug effects; D003315:Cornea / Q000187:drug effects; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009798:Ocular Hypertension / Q000188:drug therapy / Q000503:physiopathology; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D011446:Prospective Studies; D011460:Prostaglandins F / Q000009:adverse effects / Q000627:therapeutic use*; D013030:Spain; D014065:Tonometry, Ocular
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011310:Preservatives, Pharmaceutical; D011460:Prostaglandins F; C485333:tafluprost